Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine therapy in relapsing multiple sclerosis
NL-OMON23750Phase 2Active, not recruiting
- Sponsor
- Multiple Sclerosis Internationaal, Amsterdam, The Netherlands
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Fluoxetine with Placebo (2 arms). Primary endpoint: Cumulative number of active MRI lesions. Started Jan 2004; status: active, not recruiting.
02
Drugs
fluoxetine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON23750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23750.